{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:16:51Z","timestamp":1787008611902,"version":"build-2736575974"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20\u00a0K07150"],"award-info":[{"award-number":["20\u00a0K07150"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A simple, highly sensitive and specific method based on high-performance liquid chromatography (HPLC) with ultraviolet detection was developed for the measurement of venetoclax concentrations in plasma samples. The chromatographic method employed a mobile phase of acetonitrile: 0.5% KH2PO4 (pH\u00a03.5) (80\/20, v\/v) on a CAPCELL PAK C18 UG120 column at a flow rate of 0.5\u00a0mL\/min. The quantitative method was validated based on standards described in \u201cBioanalytical Method Validation: Guidance for Industry\u201d published by the US Food and Drug Administration. The separation of venetoclax and the internal standard R051012 was satisfactory, and the chromatograms were free of interfering peaks from the biological matrix. The intra- and inter-day coefficients of variation for venetoclax assays were &amp;lt;12.9%, whereas intra- and inter-day accuracies were within 13.6%. Only 100\u00a0\u03bcL of human plasma was required to detect a lower limit of quantification of 10\u00a0ng\/mL for venetoclax. The recoveries of venetoclax extracted with an Oasis HLB cartridge were between 81 and 85%. The developed HPLC method was successfully applied to the determination of venetoclax concentrations in plasma of acute myeloid leukemia patients taking venetoclax. The degree of drug interactions between venetoclax and CYP3A4 inhibitors can be determined by this HPLC assay.<\/jats:p>","DOI":"10.1093\/chromsci\/bmac080","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T08:18:04Z","timestamp":1664353084000},"page":"58-64","source":"Crossref","is-referenced-by-count":7,"title":["Quantitation of Venetoclax in Human Plasma by High-Performance Liquid Chromatography with Ultraviolet Detection"],"prefix":"10.1093","volume":"62","author":[{"given":"Natsuki","family":"Fukuda","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Akita University Hospital , Akita, 010-8543 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine , Akita, 010-8543 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honami","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine , Akita, 010-8543 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Akamine","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Akita University Hospital , Akita, 010-8543 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine , Akita, 010-8543 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7120-2425","authenticated-orcid":false,"given":"Masatomo","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Akita University Hospital , Akita, 010-8543 , Japan"},{"name":"Department of Pharmacokinetics, Akita University Graduate School of Medicine , Akita, 010-8543 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"2024010308484885100_ref1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreatedacute myeloidleukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"2024010308484885100_ref2","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"2024010308484885100_ref3","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"The American Journal of Hematology"},{"key":"2024010308484885100_ref4","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/cncr.33508","article-title":"Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia","volume":"127","author":"Rausch","year":"2021","journal-title":"Cancer"},{"key":"2024010308484885100_ref5","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"The New England Journal of Medicine"},{"key":"2024010308484885100_ref6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/dmd.116.071613","article-title":"Metabolism and disposition of a novel B-cell lymphoma-2 inhibitor venetoclax in humans and characterization of its unusual metabolites","volume":"45","author":"Liu","year":"2017","journal-title":"Drug Metabolism & Disposition"},{"key":"2024010308484885100_ref7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200038020-00002","article-title":"Effects of the antifungal agents on oxidative drug metabolism: clinical relevance","volume":"38","author":"Venkatakrishnan","year":"2000","journal-title":"Clinical Pharmacokinetics"},{"key":"2024010308484885100_ref8","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1248\/bpb.28.1805","article-title":"Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes","volume":"28","author":"Niwa","year":"2005","journal-title":"Biological and Pharmaceutical Bulletin"},{"key":"2024010308484885100_ref9","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1124\/dmd.118.082032","article-title":"Comparison of antifungal azole interactions with adult cytochrome P450 3A4 versus neonatal cytochrome P450 3A","volume":"46","author":"Godamudunage","year":"2018","journal-title":"Drug Metabolism & Disposition"},{"key":"2024010308484885100_ref10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clinical Therapeutics"},{"key":"2024010308484885100_ref11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40261-016-0485-9","article-title":"Evaluation of the pharmacokinetic interaction between venetoclax, a selective BCL-2 inhibitor, and warfarin in healthy volunteers","volume":"37","author":"Salem","year":"2017","journal-title":"Clinical Drug Investigation"},{"key":"2024010308484885100_ref12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5530\/jyp.2018.10.87","article-title":"Evaluation of deuterium-labeled internal standard for the measurement of venetoclax by HPLC-ESI -tandem mass spectrometry","volume":"10","author":"Inturi","year":"2018","journal-title":"Journal of Young Pharmacists"},{"key":"2024010308484885100_ref13","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3390\/molecules27051607","article-title":"Quantification of venetoclax for therapeutic drug monitoring in Chinese acute myeloid leukemia patients by a validated UPLC-MS\/MS method","volume":"27","author":"Yang","year":"2022","journal-title":"Molecules"},{"key":"2024010308484885100_ref14","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1208\/s12248-016-9927-9","article-title":"Clinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and non-Hodgkin's lymphoma patients: a pooled population pharmacokinetic analysis","volume":"18","author":"Jones","year":"2016","journal-title":"The AAPS Journal"},{"key":"2024010308484885100_ref15","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bcp.13175","article-title":"Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma","volume":"83","author":"Agarwal","year":"2017","journal-title":"The British Journal of Clinical Pharmacology"},{"key":"2024010308484885100_ref16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00228-017-2403-3","article-title":"Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics","volume":"74","author":"Freise","year":"2018","journal-title":"The European Journal of Clinical Pharmacology"},{"key":"2024010308484885100_ref17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/cpdd.395","article-title":"Pharmacokinetics of the BCL-2 inhibitor venetoclax in healthy Chinese subjects","volume":"7","author":"Cheung","year":"2018","journal-title":"Clinical Pharmacology in Drug Development"},{"key":"2024010308484885100_ref23","article-title":"Determination of venetoclax concentration in plasma using high-performance liquid chromatography","volume":"5","author":"Yasu","year":"2022","journal-title":"Journal of Chromatographic Science"},{"key":"2024010308484885100_ref18","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1258\/acb.2010.010029","article-title":"A simple, sensitive high-performance liquid chromatography -ultraviolet method for the quantification of concentration and steady-state pharmacokinetics of itraconazole and hydroxyitraconazole","volume":"47","author":"Miura","year":"2010","journal-title":"Annals of Clinical Biochemistry"},{"key":"2024010308484885100_ref19","volume-title":"Guidance for industry, bioanalytical method validation.","author":"US Food and Drug Administration","year":"2018"},{"key":"2024010308484885100_ref20","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/jjco\/hyab018","article-title":"Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings","volume":"51","author":"Taniguchi","year":"2021","journal-title":"The Japanese Journal of Clinical Oncology"},{"key":"2024010308484885100_ref21","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/jcph.730","article-title":"Evaluation of rifampin's transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a BCL-2 inhibitor: results of a single- and multiple-dose study","volume":"56","author":"Agarwal","year":"2016","journal-title":"The Journal of Clinical Pharmacology"},{"key":"2024010308484885100_ref22","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.21037\/jtd.2019.09.06","article-title":"Effect of rifampicin and clarithromycin on the CYP3A activity in patients with Mycobacterium avium complex","volume":"11","author":"Akiyama","year":"2019","journal-title":"The Journal of Thoracic Disease"},{"key":"2024010308484885100_ref24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.dmpk.2015.09.002","article-title":"Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC-MS\/MS methods","volume":"31","author":"Miura","year":"2016","journal-title":"Drug Metabolism and Pharmacokinetics"}],"container-title":["Journal of Chromatographic Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/62\/1\/58\/54928725\/bmac080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/62\/1\/58\/54928725\/bmac080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T17:14:50Z","timestamp":1728062090000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/chromsci\/article\/62\/1\/58\/6782836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,10,31]]},"published-print":{"date-parts":[[2023,12,30]]}},"URL":"https:\/\/doi.org\/10.1093\/chromsci\/bmac080","relation":{},"ISSN":["0021-9665","1945-239X"],"issn-type":[{"value":"0021-9665","type":"print"},{"value":"1945-239X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2022,10,31]]}}}